JTO Clinical and Research Reports最新文献

{"title":"Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression","authors":"Alvin H.K. Cheung MBBS, PhD ,&nbsp;Zeta Mui MPhil ,&nbsp;Walter W. Yeung PhD ,&nbsp;Chit Chow PhD ,&nbsp;Mandy F. Yu BSc ,&nbsp;Olivia H. Chen MD, PhD ,&nbsp;Kit-Yee Wong MPhil ,&nbsp;Fuda Xie MPhil ,&nbsp;Yat Ming Lau MBBS ,&nbsp;Alfred S-L. Cheng PhD ,&nbsp;Wei Kang PhD ,&nbsp;Ka-Fai To MBChB ,&nbsp;Tony S. Mok MD ,&nbsp;Molly S.C. Li MBBS","doi":"10.1016/j.jtocrr.2024.100754","DOIUrl":"10.1016/j.jtocrr.2024.100754","url":null,"abstract":"<div><h3>Introduction</h3><div>The germline human leukocyte antigen (HLA) status has been found to be associated with immunotherapy outcomes in patients with NSCLC, but its correlation to immunotherapy-induced pneumonitis and prognostic impact in the Asian population remains largely unknown.</div></div><div><h3>Methods</h3><div>We evaluated the HLA genotype of the germline and available tumor samples in 42 patients with programmed death-ligand 1 expression of 50% or higher undergoing pembrolizumab immunotherapy. The HLA allele expression was correlated with tumor response, disease survival, and the occurrence of pneumonitis.</div></div><div><h3>Results</h3><div>It was observed that the germline HLA-C homozygosity and HLA-DRB1∗13 expression were related to a worse progression-free survival and treatment response. Importantly, all patients (7/7 patients) who developed pneumonitis in our cohort expressed the HLA-DPB1∗02 allele, and the incidence of pneumonitis was 31.8% (7/22 patients) in patients expressing this allele compared with 0% (0/20 patients) in those without this allele (<em>p</em> = 0.009). Investigation of the tumor samples from 15 patients revealed some degree of HLA loss in the HLA class I loci in 40% (6/15) of patients, and no significant difference in tumor mutation burden was found among patients with different treatment responses.</div></div><div><h3>Conclusion</h3><div>Taken together, this study evaluated the impact of HLA status in both germline and tumor samples in patients with NSCLC with high programmed death-ligand 1 expression, and the high incidence of immunotherapy-induced pneumonitis in patients expressing the HLA-DPB1∗02 allele may suggest a routine HLA typing and closer monitoring in this patient subset.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 1","pages":"Article 100754"},"PeriodicalIF":3.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer","authors":"Mitchell S. von Itzstein MD ,&nbsp;Jialiang Liu PhD ,&nbsp;Hong Mu-Mosley PhD ,&nbsp;Farjana Fattah PhD ,&nbsp;Jason Y. Park MD, PhD ,&nbsp;Jeffrey A. SoRelle MD ,&nbsp;J. David Farrar PhD ,&nbsp;Mary E. Gwin MD ,&nbsp;David Hsiehchen MD ,&nbsp;Yvonne Gloria-McCutchen ,&nbsp;Edward K. Wakeland PhD ,&nbsp;Suzanne Cole MD ,&nbsp;Sheena Bhalla MD ,&nbsp;Radhika Kainthla MD ,&nbsp;Igor Puzanov MD, MSCI ,&nbsp;Benjamin Switzer DO, MHSA, MS ,&nbsp;Gregory A. Daniels MD, PhD ,&nbsp;Yousef Zakharia MD ,&nbsp;Montaser Shaheen MD ,&nbsp;Jianjun Zhang MD, PhD ,&nbsp;David E. Gerber MD","doi":"10.1016/j.jtocrr.2024.100751","DOIUrl":"10.1016/j.jtocrr.2024.100751","url":null,"abstract":"<div><h3>Introduction</h3><div>Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in Black and White patients with lung cancer.</div></div><div><h3>Methods</h3><div>Patients scheduled to receive cancer immunotherapy were enrolled in a multi-institutional prospective biospecimen collection registry. Clinical and demographic information were obtained from electronic medical records. Pretreatment peripheral blood samples were collected and analyzed for cytokines using a multiplex panel and for immune cell populations using mass cytometry. Differences between Black and White patients were determined and corrected for multiple comparisons.</div></div><div><h3>Results</h3><div>A total of 187 patients with NSCLC (Black, 19; White, 168) were included in the analysis. Compared with White patients, Black patients had greater comorbidity (median Charlson Comorbidity Index 5 versus 3; <em>p</em> = 0.04) and were more likely to have received previous chemotherapy (79% versus 47%; <em>p</em> = 0.03). Black patients had significantly lower levels of CCL23 and CCL27 and significantly higher levels of CCL8, CXCL1, CCL26, CCL25, CCL1, IL-1b, CXCL16, and IFN-γ (all <em>p</em> &lt; 0.05, false discovery rate &lt; 0.1). Black patients also exhibited greater populations of nonclassical CD16+ monocytes, NKT-like cells, CD4+ cells, CD38+ monocytes, and CD57+ gamma delta T cells (all <em>p</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Black and White patients with lung cancer exhibit several differences in immune parameters, with Black patients exhibiting greater levels of numerous proinflammatory cytokines and cell populations. The etiology and clinical significance of these differences warrant further evaluation.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 1","pages":"Article 100751"},"PeriodicalIF":3.0,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142656219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report","authors":"Alissa J. Cooper MD ,&nbsp;Natasha Rekhtman MD, PhD ,&nbsp;Marina K. Baine MD, PhD ,&nbsp;Marie C. Thomas DNP, FNP-C ,&nbsp;Alia C. Lynch PharmD, BCOP ,&nbsp;Ryan D. Gentzler MD, MS","doi":"10.1016/j.jtocrr.2024.100750","DOIUrl":"10.1016/j.jtocrr.2024.100750","url":null,"abstract":"<div><div>Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-expressing metastatic pulmonary carcinoid tumor, a clinical entity without many approved management options. Here, we report the case of a patient with metastatic atypical carcinoid tumor which had progressed on multiple previous therapies. Her tumor strongly expressed DLL3 protein and had clinical response to tarlatamab therapy. This case indicates that this novel therapy may be an efficacious option in other pulmonary neuroendocrine cancers.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100750"},"PeriodicalIF":3.0,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Response to the Letter to the Editor: “Heart and Lung Dose as Predictors of Overall Survival in Patients With Locally Advanced Lung Cancer: A National Multicenter Study”","authors":"Agon Olloni MD, PhD,&nbsp;Carsten Brink PhD,&nbsp;Ebbe L. Lorenzen PhD,&nbsp;Stefan S. Jeppesen MD, PhD,&nbsp;Tine Schytte MD, PhD","doi":"10.1016/j.jtocrr.2024.100749","DOIUrl":"10.1016/j.jtocrr.2024.100749","url":null,"abstract":"","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100749"},"PeriodicalIF":3.0,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief Report of a New Anatomical Region at Risk in Thoracic Radiotherapy: From Discovery to Implementation","authors":"Kathryn Banfill PhD, FRCR ,&nbsp;Thomas Marchant PhD ,&nbsp;Alan McWilliam PhD ,&nbsp;Joseph Wood PhD ,&nbsp;Matthias Schmitt MD, PhD ,&nbsp;Azadeh Abravan PhD ,&nbsp;Gareth Price PhD ,&nbsp;Marcel van Herk PhD ,&nbsp;Corinne Faivre-Finn PhD, FRCR","doi":"10.1016/j.jtocrr.2024.100742","DOIUrl":"10.1016/j.jtocrr.2024.100742","url":null,"abstract":"<div><div>Increasing radiotherapy dose to select cardiac structures is associated with cardiac events and premature death. Previous studies have found a dose–response relationship for structures at the base of the heart.</div><div>We have defined a new cardiac anatomical region at risk for radiotherapy by consensus opinion, based on image-based data-mining studies. The cardiac avoidance area comprises the superior vena cava, right atrium, aortic root, left main coronary artery, and proximal segments of the left anterior descending and right coronary arteries. We describe a contouring atlas for the cardiac avoidance area to facilitate implementation.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100742"},"PeriodicalIF":3.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC","authors":"Jacqueline V. Aredo MD, MS ,&nbsp;Heather A. Wakelee MD ,&nbsp;Kavitha J. Ramchandran MD ,&nbsp;Joel W. Neal MD, PhD ,&nbsp;Maximilian Diehn MD, PhD ,&nbsp;Angela Bik-Yu Hui PhD ,&nbsp;Ameen Salahudeen MD, PhD ,&nbsp;Bernice Kwong MD ,&nbsp;Gerald J. Berry MD ,&nbsp;H. Henry Guo MD, PhD ,&nbsp;Kristen Cunanan PhD ,&nbsp;Shireen Vali PhD ,&nbsp;Danny Pancirer BA ,&nbsp;Vivian Tsang MSN ,&nbsp;Grace Hwang MS ,&nbsp;Monica Loza BA ,&nbsp;Brittany Johnson BA ,&nbsp;Isabelle Blanchard BS ,&nbsp;Sukhmani K. Padda MD","doi":"10.1016/j.jtocrr.2024.100741","DOIUrl":"10.1016/j.jtocrr.2024.100741","url":null,"abstract":"<div><h3>Introduction</h3><div>There are no standard targeted treatment options for advanced <em>KRAS</em>-mutant NSCLC beyond <em>KRAS</em> G12C inhibitors. A computational model identified regorafenib and low-dose methotrexate as synergistic in preclinical models of <em>KRAS</em>-mutant NSCLC. This study evaluated the efficacy and safety of the combination in previously treated advanced <em>KRAS</em>-mutant NSCLC.</div></div><div><h3>Methods</h3><div>This single-arm phase II study included regorafenib 80 to 120 mg oral daily and oral methotrexate dose escalated to tolerability from 10 to 20 mg twice weekly during the first cycle. Both agents were administered on weeks 1 to 3 of each 4-week cycle. The primary end point was progression-free survival.</div></div><div><h3>Results</h3><div>In total, 18 patients with <em>KRAS</em>-mutant NSCLC were enrolled. Five patients received regorafenib at a 120 mg starting dose with four discontinuing due to toxicity; subsequently, 13 patients were treated at an 80 mg starting dose, with eight dose-escalating to 120 mg after the first cycle. Median progression-free survival was 3.7 months (95% confidence interval 1.8–8.6) and median overall survival was 10.4 months (95% confidence interval 5.2–30.3). The objective response rate was 16.7% and the 8-week disease control rate was 66.7%. Grade 3 treatment-related adverse events occurred in 11 patients, most often oral mucositis (n = 2) and asymptomatic lipase increase (n = 2). One patient developed asymptomatic grade 4 lipase increase.</div></div><div><h3>Conclusions</h3><div>Combination treatment of regorafenib and oral methotrexate in patients with <em>KRAS</em>-mutant NSCLC was limited due to toxicity, and the study did not meet its primary end point. Computational modeling may aid in repurposing therapeutic options though caution must be exercised with tolerability.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100741"},"PeriodicalIF":3.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report","authors":"Mehraab N. Majeed MBBCh ,&nbsp;Subramanian Venkatesan PhD ,&nbsp;Dionysis Papadatos-Pastos PhD ,&nbsp;Tanya Ahmad MD ,&nbsp;Martin Forster PhD ,&nbsp;Polyvios Demetriades MRCP ,&nbsp;Daniel Johnathan Hughes MRCP ,&nbsp;Sarah Benafif PhD ,&nbsp;Siow Ming Lee FRCP","doi":"10.1016/j.jtocrr.2024.100746","DOIUrl":"10.1016/j.jtocrr.2024.100746","url":null,"abstract":"<div><div>A 72-year-old man presented to his general practitioner with worsening dyspnea and was diagnosed with having recurrent <em>ROS1</em>-positive stage IIIB NSCLC 8 years after initial diagnosis and radical treatment for early stage disease. He was subsequently started on entrectinib but required hospital admissions for recurrent acute kidney injuries on a background of chronic kidney disease. His entrectinib was withheld on day 20 since his first dose of treatment while he was being investigated. Nevertheless, he continued to experience worsening dyspnea and bilateral pedal edema and later developed acute pulmonary edema 31 days after his first dose of entrectinib, despite the drug being withheld for the past 11 days. Results of biochemical tests and cardiac imaging confirmed acute myocarditis. Initially, he was treated with standard heart failure medications without clinical improvement or decline in N-terminal pro B-type natriuretic peptide levels. Nevertheless, he noticed significant improvement after starting a short course of prednisolone, which led to complete resolution of symptoms, improved N-terminal pro B-type natriuretic peptide levels, and recovery of left ventricular ejection fraction. His treatment was subsequently changed to crizotinib, which was well tolerated. This is the third reported case of entrectinib-induced myocarditis and the first reported case which has been successfully managed with steroid therapy. This case was also associated with concurrent acute heart failure after entrectinib treatment which responded promptly to prednisolone (40 mg). Entrectinib-induced cardiotoxicity is an important adverse event to be aware of, particularly as patients may be asymptomatic for an initial period before significant deterioration.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100746"},"PeriodicalIF":3.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC","authors":"Francesca Lucibello MD ,&nbsp;Valérie Gounant MD, PhD ,&nbsp;Mihaela Aldea MD, PhD ,&nbsp;Michaël Duruisseaux MD, PhD ,&nbsp;Maurice Perol MD ,&nbsp;Christos Chouaid MD ,&nbsp;Jaafar Bennouna MD, PhD ,&nbsp;Vincent Fallet MD ,&nbsp;Aldo Renault MD ,&nbsp;Florian Guisier MD, PhD ,&nbsp;Etienne Giroux-Leprieur MD, PhD ,&nbsp;Marie Wislez MD, PhD ,&nbsp;Anne-Claire Toffart MD, PhD ,&nbsp;Julien Mazieres MD, PhD ,&nbsp;Clémence Basse MD, PhD ,&nbsp;Nadia Hegarat PhD ,&nbsp;Matthieu Carton MD ,&nbsp;Nicolas Girard MD, PhD","doi":"10.1016/j.jtocrr.2024.100743","DOIUrl":"10.1016/j.jtocrr.2024.100743","url":null,"abstract":"<div><h3>Introduction</h3><div>Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, <em>RET</em> fusion-positive NSCLC.</div></div><div><h3>Objective</h3><div>To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET fusion-positive NSCLC.</div></div><div><h3>Design</h3><div>Retrospective study of consecutive patients enrolled in the French expanded-access program for pralsetinib from December 1, 2019, to December 31, 2021.</div></div><div><h3>Participants</h3><div>A total of 41 patients with advanced, refractory, <em>RET</em> fusion-positive NSCLC were included. Pralsetinib was administered at a daily dose of 400 mg based on safety and pharmacokinetic outcomes from previous phase 1/2 study.</div></div><div><h3>Results</h3><div>Pralsetinib was administered as second line in 23 patients (56%) and as third line and beyond in 15 patients (37%). After a median follow-up of 26.3 months, pralsetinib was ongoing in 13 patients. Median real-world progression-free survival was 11.8 (95% confidence interval [CI]: 9.3–15.5) months. Objective response rate was 68% (95% CI: 50%–82%), and disease control rate was 89% (95% CI: 75%–97%). Subsequent line of systemic therapy was initiated in 11 patients. Median overall survival from pralsetinib initiation was 23.8 (95% CI: 16.5–not reached) months.</div></div><div><h3>Conclusion</h3><div>In this extensive real-world cohort of patients with advanced or metastatic NSCLC harboring RET fusions, we highlight the antitumor efficacy of pralsetinib, particularly when administered in later treatment lines. We also observe the aggressive nature of disease progression, frequent utilization of chemotherapy and antiangiogenic agents as initial subsequent therapies, and limited insight into resistance mechanisms due to infrequent rebiopsy and genomic profiling at progression.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"6 1","pages":"Article 100743"},"PeriodicalIF":3.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142704942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multisite Randomized Controlled Trial of CareSTEPS: A Supportive Care Intervention for the Family Caregivers of Patients With Advanced Lung Cancer","authors":"Maria L. Rangel DrPH ,&nbsp;Kathrin Milbury PhD ,&nbsp;Karen Kayser PhD ,&nbsp;Robert Taylor Ripley MD ,&nbsp;Elizabeth Kvale MD ,&nbsp;Hoda Badr PhD","doi":"10.1016/j.jtocrr.2024.100736","DOIUrl":"10.1016/j.jtocrr.2024.100736","url":null,"abstract":"<div><h3>Objectives</h3><div>Patients with advanced lung cancer (LC) face significant physical, psychological, and functional challenges, increasing their reliance on caregivers for practical and emotional support. This study evaluates the efficacy of CareSTEPS (Self-<u>Care</u>, <u>S</u>tress management, Symp<u>t</u>om management, <u>E</u>ffective communication, Problem-solving, and Social support), a 6-week telephone-delivered intervention designed to improve psychological functioning (depression and anxiety symptoms) and reduce caregiver burden among family caregivers of patients with advanced LC.</div></div><div><h3>Methods</h3><div>In this multisite, open-label, parallel-group randomized controlled trial, 174 caregivers (74.1% female individuals, 40.2% from a racial or ethnic minority group) of patients with stage IIIB or IV NSCLC or extensive-stage SCLC completed baseline surveys and were randomly assigned to CareSTEPS (n = 87) or usual care (n = 87) using stratified block randomization. Caregivers in the CareSTEPS arm received a manual with information on self-care, stress management, symptom management, effective communication, problem-solving, and social support. They also participated in six weekly telephone sessions with Masters-level trained interventionists with a mental health background, who provided psychoeducation, skills training, and support. Eight weeks after baseline, caregivers completed a follow-up survey.</div></div><div><h3>Results</h3><div>Using an intent-to-treat framework, analyses of covariance were conducted to assess the efficacy of CareSTEPS, with <em>p</em> values lower than 0.05 indicating significant differences. Caregivers who received CareSTEPS reported improved psychological functioning and lower burden compared with those who received usual care, with effect sizes ranging from small to large (depression d = −0.55, anxiety d = −0.81, burden d = −0.37).</div></div><div><h3>Conclusions</h3><div>The CareSTEPS intervention reports great promise in meeting the critical support needs of the family caregivers of patients with advanced LC, significantly improving caregivers' psychological functioning and reducing their burden. Overall, the findings emphasize the importance of incorporating caregiver support into the comprehensive management of advanced LC.</div></div><div><h3>Clinical Trial Registration</h3><div>ClinicalTrials.gov <span><span>NCT02414672</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100736"},"PeriodicalIF":3.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications","authors":"Mandy Jongbloed MD ,&nbsp;Martina Bortolot MD ,&nbsp;Leonard Wee PhD ,&nbsp;Jarno W.J. Huijs MD ,&nbsp;Murillo Bellezo PhD ,&nbsp;Rianne D.W. Vaes PhD ,&nbsp;Frank Aboubakar Nana MD, PhD ,&nbsp;Koen J. Hartemink MD, PhD ,&nbsp;Dirk K.M. De Ruysscher MD, PhD ,&nbsp;Lizza E.L. Hendriks MD, PhD","doi":"10.1016/j.jtocrr.2024.100740","DOIUrl":"10.1016/j.jtocrr.2024.100740","url":null,"abstract":"<div><div>This review discusses the current data on predictive and prognostic biomarkers in oligometastatic NSCLC and discusses whether biomarkers identified in other stages and widespread metastatic disease can be extrapolated to the oligometastatic disease (OMD) setting. Research is underway to explore the prognostic and predictive value of biological attributes of tumor tissue, circulating cells, the tumor microenvironment, and imaging findings as biomarkers of oligometastatic NSCLC. Biomarkers that help define true OMD and predict outcomes are needed for patient selection for oligometastatic treatment, and to avoid futile treatments in patients that will not benefit from locoregional treatment. Nevertheless, these biomarkers are still in the early stages of development and lack prospective validation in clinical trials. Furthermore, the absence of a clear definition of OMD contributes to a heterogeneous study population in which different types of OMD are mixed and treatment strategies are different. Multiple tissue-based, circulating, and imaging features are promising regarding their prognostic and predictive role in NSCLC, but data is still limited and might be biased owing to the inclusion of heterogeneous patient populations. Larger homogeneous and prospective series are needed to assess the prognostic and predictive role of these biomarkers. As obtaining tissue can be difficult and is invasive, the most promising tools for further evaluation are liquid biopsies and imaging-based biomarkers as these can also be used for longitudinal follow-up.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100740"},"PeriodicalIF":3.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}